Cargando…

Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion

BACKGROUND: There are two main causes of exudative effusion including malignancy-induced effusion and tuberculosis. Considering that in reactive ejections, such as tuberculosis-induced effusion, the role of B lymphocytes and in the malignant effusion, the role of T lymphocytes are more important, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehraban, Zahra, Pourdowlat, Guitti, Mortaz, Esmaeil, Atefeh, Abedini, Ghaforian, Amin R., MalAmir, Mehrdad Dargahi, Bakhtiari, Nima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041266/
https://www.ncbi.nlm.nih.gov/pubmed/36993098
http://dx.doi.org/10.4103/jfmpc.jfmpc_2296_21
_version_ 1784912676055416832
author Mehraban, Zahra
Pourdowlat, Guitti
Mortaz, Esmaeil
Atefeh, Abedini
Ghaforian, Amin R.
MalAmir, Mehrdad Dargahi
Bakhtiari, Nima
author_facet Mehraban, Zahra
Pourdowlat, Guitti
Mortaz, Esmaeil
Atefeh, Abedini
Ghaforian, Amin R.
MalAmir, Mehrdad Dargahi
Bakhtiari, Nima
author_sort Mehraban, Zahra
collection PubMed
description BACKGROUND: There are two main causes of exudative effusion including malignancy-induced effusion and tuberculosis. Considering that in reactive ejections, such as tuberculosis-induced effusion, the role of B lymphocytes and in the malignant effusion, the role of T lymphocytes are more important, in this study we analyzed the frequency of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON in the pleural and serum samples of patients with exudative lymphocytic-dominant effusion. METHODS: In total, 73 patients were enrolled in the study by exudative lymphocyte effusion, and finally, 63 patients had definite diagnoses. The patients were sorted into three groups including malignant, tuberculosis, and none. The sample of blood plasma and pleural effusion were collected and CD markers were analyzed using flow cytometry. RESULTS: The mean age in the malignancy and tuberculous (TB) groups was 63.16 ± 12 and 52.15 ± 22.62, respectively. There was no significant difference in the frequency of CD8, CD4, and CD16-56 cells in blood samples of patients with tuberculosis and malignancy. Compared to those with tuberculosis, the percentage of CD64 cells was significantly higher in patients with tuberculosis than in malignant subjects. Moreover, a comparison of the frequency of cells with CD8, CD4, CD19, CD64, CD16-56, and CD14 markers in pleural samples showed no significant difference between groups. Other inflammatory factors were also investigated. The erythrocyte sedimentation rate (ESR) value for tuberculosis patients was significantly higher than malignancy. Also, QuantiFERON was positive in 14.3% of malignant patients, and 62.5% of patients with TB, which had a significant difference. CONCLUSION: Considering that there are many confounding variables in the study, such as previous medications, subtypes of Mycobacterium, and race of patients conducting studies in different groups and performing data mining for using a set of parameters can be used to detect the exact diagnosis.
format Online
Article
Text
id pubmed-10041266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-100412662023-03-28 Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion Mehraban, Zahra Pourdowlat, Guitti Mortaz, Esmaeil Atefeh, Abedini Ghaforian, Amin R. MalAmir, Mehrdad Dargahi Bakhtiari, Nima J Family Med Prim Care Original Article BACKGROUND: There are two main causes of exudative effusion including malignancy-induced effusion and tuberculosis. Considering that in reactive ejections, such as tuberculosis-induced effusion, the role of B lymphocytes and in the malignant effusion, the role of T lymphocytes are more important, in this study we analyzed the frequency of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON in the pleural and serum samples of patients with exudative lymphocytic-dominant effusion. METHODS: In total, 73 patients were enrolled in the study by exudative lymphocyte effusion, and finally, 63 patients had definite diagnoses. The patients were sorted into three groups including malignant, tuberculosis, and none. The sample of blood plasma and pleural effusion were collected and CD markers were analyzed using flow cytometry. RESULTS: The mean age in the malignancy and tuberculous (TB) groups was 63.16 ± 12 and 52.15 ± 22.62, respectively. There was no significant difference in the frequency of CD8, CD4, and CD16-56 cells in blood samples of patients with tuberculosis and malignancy. Compared to those with tuberculosis, the percentage of CD64 cells was significantly higher in patients with tuberculosis than in malignant subjects. Moreover, a comparison of the frequency of cells with CD8, CD4, CD19, CD64, CD16-56, and CD14 markers in pleural samples showed no significant difference between groups. Other inflammatory factors were also investigated. The erythrocyte sedimentation rate (ESR) value for tuberculosis patients was significantly higher than malignancy. Also, QuantiFERON was positive in 14.3% of malignant patients, and 62.5% of patients with TB, which had a significant difference. CONCLUSION: Considering that there are many confounding variables in the study, such as previous medications, subtypes of Mycobacterium, and race of patients conducting studies in different groups and performing data mining for using a set of parameters can be used to detect the exact diagnosis. Wolters Kluwer - Medknow 2022-11 2022-12-16 /pmc/articles/PMC10041266/ /pubmed/36993098 http://dx.doi.org/10.4103/jfmpc.jfmpc_2296_21 Text en Copyright: © 2022 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Mehraban, Zahra
Pourdowlat, Guitti
Mortaz, Esmaeil
Atefeh, Abedini
Ghaforian, Amin R.
MalAmir, Mehrdad Dargahi
Bakhtiari, Nima
Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion
title Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion
title_full Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion
title_fullStr Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion
title_full_unstemmed Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion
title_short Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion
title_sort analysis of cd4, cd8, cd19, cd56-16, cd64, quantiferon biomarkers in exudative lymphocyte-dominant pleural effusion
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041266/
https://www.ncbi.nlm.nih.gov/pubmed/36993098
http://dx.doi.org/10.4103/jfmpc.jfmpc_2296_21
work_keys_str_mv AT mehrabanzahra analysisofcd4cd8cd19cd5616cd64quantiferonbiomarkersinexudativelymphocytedominantpleuraleffusion
AT pourdowlatguitti analysisofcd4cd8cd19cd5616cd64quantiferonbiomarkersinexudativelymphocytedominantpleuraleffusion
AT mortazesmaeil analysisofcd4cd8cd19cd5616cd64quantiferonbiomarkersinexudativelymphocytedominantpleuraleffusion
AT atefehabedini analysisofcd4cd8cd19cd5616cd64quantiferonbiomarkersinexudativelymphocytedominantpleuraleffusion
AT ghaforianaminr analysisofcd4cd8cd19cd5616cd64quantiferonbiomarkersinexudativelymphocytedominantpleuraleffusion
AT malamirmehrdaddargahi analysisofcd4cd8cd19cd5616cd64quantiferonbiomarkersinexudativelymphocytedominantpleuraleffusion
AT bakhtiarinima analysisofcd4cd8cd19cd5616cd64quantiferonbiomarkersinexudativelymphocytedominantpleuraleffusion